(DH) Definitive Healthcare - Ratings and Ratios

Definitive Healthcare Corp. is a SaaS provider of healthcare commercial intelligence, offering a comprehensive platform that enables clients to make informed decisions across various stages, from product development to sales and marketing execution. The companys platform aggregates data on healthcare providers, allowing its customers to optimize their strategies in areas such as sales, marketing, clinical research, and physician network management.

With a diverse client base that includes biopharmaceutical and medical device companies, healthcare IT firms, and healthcare providers, Definitive Healthcare Corp. plays a crucial role in the healthcare ecosystem. Its services also extend to other industries related to healthcare, such as staffing, commercial real estate, and financial institutions. By providing actionable insights, the company facilitates more effective go-to-market planning and execution for its clients.

Analyzing the companys , we observe that the stock has been trending upwards, with its last price at $3.69, above both its 20-day and 50-day simple moving averages (SMA20 and SMA50) of $2.71 and $2.73, respectively. However, it remains below its 200-day SMA of $4.05, indicating a potential long-term downtrend. The average true range (ATR) of $0.20, or 5.46% of the last price, suggests moderate volatility.

Considering the , Definitive Healthcare Corp.s market capitalization stands at $299.06 million, with a forward P/E ratio of 13.19, indicating the markets expectations for future earnings growth. However, the current lack of a P/E ratio and a negative return on equity (RoE) of -67.28% raise concerns about the companys current profitability.

Based on both and , a forecast for Definitive Healthcare Corp. (DH) could be constructed. Given the stocks current position above its short-term moving averages but below its long-term SMA, a potential buy signal could be generated if it surpasses the $4.05 level with significant volume, indicating a possible reversal of the long-term downtrend. Additionally, if the company can demonstrate significant improvement in its RoE and achieve profitability, it could lead to a re-evaluation of its stock, potentially driving the price upwards. A target price could be set around $5.50, based on a combination of technical indicators and fundamental analysis, representing a potential upside of approximately 49% from the current price.